Alexion to Present 16 Rare Disease Studies at ASBMR 2026

Executive Summary

• Alexion, AstraZeneca Rare Disease, will deliver 16 presentations, including three oral presentations, at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Boston, Massachusetts, from 9 to 12 October 2026, according to AstraZeneca Press Releases.
• Results from the Phase III HICKORY trial of efzimfotase alfa (ALXN1850) in treatment-naïve adolescents and adults with hypophosphatasia will be presented as an oral presentation on 11 October 2026, the company said.
• CALYPSO Phase III data on skeletal parameters for eneboparatide, an investigational parathyroid hormone (PTH) 1 receptor agonist, in adults with chronic hypoparathyroidism will also be presented orally, per the same statement.
• Gianluca Pirozzi, Senior Vice President, Head of Development, Regulatory and Safety, Alexion, framed the meeting as demonstrating the breadth of the company's research in HPP and HypoPT, two rare, multisystemic diseases, the release states.

Key Takeaways

• Alexion's ASBMR 2026 presence is built around three oral presentations and 13 posters spanning hypophosphatasia, chronic hypoparathyroidism and early research.
• The HICKORY readout is positioned by the company as adding evidence for efzimfotase alfa in a broad HPP population, including the first Phase III trial to include patients with adult-onset disease.
• CALYPSO skeletal-parameter data extend the evidence base for eneboparatide, which remains investigational.
• Supporting presentations cover disease burden, diagnosis, epidemiology and real-world survey work rather than new pivotal efficacy claims.

What Alexion Will Present at ASBMR 2026

Alexion's schedule at the Boston meeting runs from 9 to 12 October 2026. The three oral presentations are the HICKORY Phase III results for efzimfotase alfa in treatment-naïve adolescents and adults with hypophosphatasia, the CALYPSO Phase III analysis of balanced effects of eneboparatide on skeletal parameters, and a plasma proteomics abstract on clinical expression in ADO.

The remaining 13 presentations are poster sessions, covering genetic characterisation of adults with HPP in the United States, a UK Delphi study on disease burden and management, an at-home digital assessment toolkit, treatment experience from a US survey, clinical course and candidate biomarkers in perinatal HPP, diagnostic delay, holistic disease burden, cascade diagnosis within families, and several chronic hypoparathyroidism epidemiology and bone-manifestation studies. One late-breaking poster examines methodological limits on an indirect treatment comparison between CALYPSO (eneboparatide) and the PaTHway (palopegteriparatide) trial.

Efzimfotase Alfa and the HICKORY Phase III Readout

The HICKORY abstract, authored by K. Dahir, is titled "Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Adolescents and Adults with Hypophosphatasia (HPP): Results of HICKORY as Part of a Three-Trial Phase 3 Clinical Program." It is scheduled as oral presentation #1116 on 11 October 2026 from 05:00 to 05:12 PM ET.

Alexion states that HICKORY is the first Phase III clinical trial to include patients with adult-onset disease. Pirozzi said the results "will further reinforce the potential of efzimfotase alfa to reduce treatment burden and redefine care expectations." That framing is a company claim about potential; the abstract itself is the evidence investors and clinicians will read. The reference to a three-trial Phase 3 program indicates HICKORY is one component of a broader registration package, though the release gives no timeline for regulatory filing.

Eneboparatide and CALYPSO Skeletal Data

The CALYPSO abstract, authored by A. Khan, reports balanced effects of eneboparatide on skeletal parameters from a Phase 3, randomized, placebo-controlled study in adults with chronic hypoparathyroidism. It is scheduled as oral presentation #1089 on 11 October 2026 from 12:06 to 12:18 PM ET. Alexion describes eneboparatide as an investigational parathyroid hormone (PTH) 1 receptor agonist, so no approved product claim is made.

Related: AMD Q2 2026: Record $11.5B Revenue as Data Center More Than Doubles — Helios, MI400, and the ROCm Software Pivot

A separate late-breaking poster by M. Erdmann addresses methodological differences that limit the feasibility of an indirect treatment comparison between CALYPSO and the PaTHway trial of palopegteriparatide. The inclusion of that abstract suggests Alexion expects cross-trial comparison questions from the clinical community and is pre-empting them with a methods-focused presentation. Two further posters by H. Siggelkow cover electronic health record data capture and bone manifestations in chronic hypoparathyroidism; D. Vizcaya presents prevalence and incidence data for the US from 2018 to 2024 and epidemiology of low bone density and osteoporosis.

Hypophosphatasia Evidence Beyond the Pivotal Trial

Alexion's HPP poster set is weighted toward burden of illness and diagnosis rather than efficacy. Peroutka, C. presents genetic characterisation and clinical manifestations in US adults; Moss, K. reports a UK Delphi study on diagnosis, assessment and management; Dahir, K. presents a multicenter observational study on an at-home digital assessment toolkit; Lynch, L. reports a US survey on treatment experience; Ohata, Y. covers clinical course and candidate biomarkers in perinatal HPP; Padidela, R. examines diagnostic delay in a cross-sectional multinational study; Dhaliwal, R. characterises holistic disease burden in US adults; and Tanfous, M. presents a case series on cascade diagnosis within families.

For deeper context, see our Biotech & Pharma analysis: "Tozaro & Mercia Target Gene Therapy Cost Barriers in 2026".

Taken together, the poster slate is designed to document diagnostic delay, disease burden and real-world treatment experience alongside the pivotal HICKORY readout. For payers and health systems, that material can matter as much as efficacy data when access and reimbursement discussions begin.

ASBMR 2026 Presentation Signals

The source does not disclose financial terms, market size estimates or regulatory filing timelines for either efzimfotase alfa or eneboparatide, and none are inferred here.

Additional coverage: World & Tinder Expand Human Verification Integration 2026

AstraZeneca Implementation Risks

The release does not quantify commercial forecasts, pricing, or filing dates, so the principal risks are evidentiary rather than financial at this stage. The HICKORY and CALYPSO results are being previewed by abstract title only; safety and efficacy outcomes will be judged on the presented data, not on the release language. Alexion's own inclusion of a poster on indirect treatment comparison limitations signals that cross-trial comparisons with competing hypoparathyroidism therapies are a live methodological issue. Both efzimfotase alfa and eneboparatide remain investigational, so any care-pathway or payer assumption built on approval timing would be premature. Diagnostic-delay and burden data may strengthen access arguments, but they do not substitute for pivotal results.

Editorial independence disclosure: this article was prepared independently from the cited company statement and does not reflect the views of AstraZeneca or Alexion. Source note: all facts in this article are drawn from the AstraZeneca Press Releases announcement dated 6 October 2026.

What This Means for Practitioners

For clinicians, procurement teams and investors tracking rare-disease bone and mineral portfolios, the practical signal is timing and composition rather than headline efficacy. Three oral presentations in a four-day meeting, with pivotal data in HPP and skeletal-parameter data in chronic hypoparathyroidism, indicate Alexion is consolidating its evidence base ahead of any regulatory or access push. Practitioners evaluating these assets should read the actual abstracts for endpoints, safety and study population, since the company release describes potential and study design but reports no numerical results. The accompanying burden-of-illness and diagnostic-delay posters are the more immediately usable material for pathway and reimbursement planning.